Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–251 of 251 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Adult Males Clear all

Conditions: Healthy Adult Male and Female Volunteers
Interventions: BICX104 naltrexone implantable pellet, Bupropion 150 mg XL, Naltrexone (depot); Drug
Lead sponsor: BioCorRx Pharmaceuticals Inc; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: Human ADME; Drug
Lead sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: Lesinurad 400 mg (Site 1), Lesinurad 400 mg (Site 2, Lot A), Lesinurad 400 mg (Site 2, Lot B); Drug
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Volunteer
Interventions: DISC-3405, Placebo; Drug
Lead sponsor: Disc Medicine, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Volunteers
Interventions: TAK-994 Oral Tablet, [14C]TAK-994 Intravenous Infusion, [14C]TAK-994 Oral Suspension; Drug
Lead sponsor: Takeda; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Subjects, Pharmacokinetics of ASP015K, Pharmacodynamics
Interventions: ASP015K, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Chronic Hepatitis B
Interventions: Vebicorvir (VBR); Drug
Lead sponsor: Assembly Biosciences; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hashimoto Disease
Interventions: MYMD-1, Placebo; Drug
Lead sponsor: TNF Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Clearwater, Florida

Conditions: Healthy
Interventions: Divalproex Sodium Extended-Release Tablets 500 mg, Depakote ER® Tablets 500 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Infections, Bacterial
Interventions: GSK1322322 1000 mg containing radioactive 14C-GSK1322322, GSK1322322 1200 mg containing radioactive 14C-GSK1322322; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 55 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Opioid-Related Disorders, Pain, Acute, Pain, Postoperative
Interventions: GRT7014 - Abuse Deterrend Tablet, Norco 5Mg-325Mg Tablet; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lenexa, Kansas

Search by objective public record fields.

Safety and PK Study of BICX104 With or Without Bupropion Compared to Vivitrol

Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects

Lesinurad Tablet Relative Bioavailability

A Study of DISC-3405 in Healthy Volunteers

Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K

A Study to Evaluate the Mass Balance Absorption and AME of VBR

Single Ascending and Multiple Dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male and Female Adult Subjects

Fasting Study of Divalproex Sodium Extended-Release Tablets 500 mg to Depakote ER® Tablets 500 mg

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults